» Articles » PMID: 17290734

Prostate Cancer: a Practical Approach to Current Management of Recurrent Disease

Overview
Journal Mayo Clin Proc
Specialty General Medicine
Date 2007 Feb 13
PMID 17290734
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate cancer is the leading cause of cancer in men in the United States, with 234,460 men expected to be diagnosed as having the disease in 2006 (33% of cancers in men), and the third leading cause of cancer deaths in men, with 27,350 men expected to die of the disease (9% of cancer deaths). Through early detection and improved local therapies, including surgery or radiation therapy, a large number of men will be cured, but unfortunately, a significant number of men will still experience relapse of disease and require continued surveillance and ongoing therapy. This article discusses approaches to treatment of men who have recurrent disease, including active surveillance, androgen ablation therapy, secondary hormone therapy, chemotherapy, bisphosphonates, radiation therapy, and future directions.

Citing Articles

The natural compound periplogenin suppresses the growth of prostate carcinoma cells by directly targeting ATP1A1.

Zhang X, Pang T, Zhang H, Horn M, Michlits G, Dyczynski M Sci Rep. 2024; 14(1):20509.

PMID: 39227746 PMC: 11372130. DOI: 10.1038/s41598-024-71722-7.


HIF1α promotes prostate cancer progression by increasing ATG5 expression.

Yu K, Xiang L, Li S, Wang S, Chen C, Mu H Anim Cells Syst (Seoul). 2019; 23(5):326-334.

PMID: 31700698 PMC: 6830197. DOI: 10.1080/19768354.2019.1658637.


Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer.

Hiroshige T, Eguchi Y, Yoshizumi O, Chikui K, Kumagai H, Kawaguchi Y Oncol Lett. 2018; 15(5):6806-6814.

PMID: 29725416 PMC: 5920147. DOI: 10.3892/ol.2018.8263.


Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy.

Geng J, Lin V, Yu C, Huang C, Yin H, Chang T Int J Mol Sci. 2016; 17(12).

PMID: 27898031 PMC: 5187770. DOI: 10.3390/ijms17121970.


A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.

Chi K, Kheoh T, Ryan C, Molina A, Bellmunt J, Vogelzang N Ann Oncol. 2015; 27(3):454-60.

PMID: 26685010 PMC: 4769990. DOI: 10.1093/annonc/mdv594.